Printer Friendly

IMMUNOGEN COMPLETES PHASE I TRIAL OF ONCOLYSIN S

 CAMBRIDGE, Mass., March 9 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the completion of its initial Phase I safety trial of Oncolysin S in patients with relapsed and refractory small-cell lung cancer. Oncolysin S, ImmunoGen's second product, is one of the company's portfolio of immunoconjugates for cancer treatment.
 "Preliminary results of this Phase I trial are encouraging," notes Carol L. Epstein, M.D., ImmunoGen vice president and chief medical officer. "We have established a highly satisfactory safety profile for Oncolysin S and have shown that the drug is well tolerated." Epstein adds that "current therapies for small-cell lung cancer rarely produce durable responses, and the prognosis for these patients following relapse is poor: Less than five percent survive long-term. While the goal of this Phase I trial was to assess the safety of the drug, we have seen biological activity, and also evidence of efficacy, which is remarkable in relapsed patients with small-cell lung cancer." The company expects data from the Phase I study to be presented at the upcoming American Society of Clinical Oncology meeting in May.
 Using the information obtained in this study, ImmunoGen will begin a dose-ranging Phase I/II clinical trial in patients who are in remission following conventional chemotherapy, to extend their period of disease- free survival. Explains Donald J. McCarren, ImmunoGen president and chief operating officer, "Based on extensive clinical experience with our lead product, Oncolysin B, we believe all of the Oncolysin products, including Oncolysin S, will be shown to be particularly effective as adjunctive therapy, to extend the disease-free interval of patients with minimal residual disease following conventional chemotherapy. This application will fill a major void in the marketplace for cancer therapy."
 ImmunoGen, Inc. develops innovative therapeutics for the treatment of cancer and immune-mediated diseases. The company produces proprietary toxins conjugated to highly specific targeting agents which search out and destroy cancer cells. The company's first-generation products, the Oncolysins, are each comprised of a highly specific monoclonal antibody linked to blocked ricin, a proprietary derivative of the powerful plant toxin, ricin. The company also is developing small- drug immunoconjugates for use as tumor debulking agents.
 -0- 3/9/93
 /CONTACT: Mark Ratner of ImmunoGen, 617-661-9312/
 (IMGN)


CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU:

TM -- NE006 -- 4354 03/09/93 08:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1993
Words:381
Previous Article:HONDO OIL & GAS RESPONDS TO BROADCAST REPORT
Next Article:DIRECTTALK/2 APPLICATIONS DEVELOPMENT SOFTWARE FROM IBM FOR DIALOGIC COMPONENTS
Topics:


Related Articles
RESULTS OF PHASE I/II TRIALS USING IMMUNOGEN'S ONCOLYSIN B SHOW POTENTIAL FOR PREVENTING RELAPSE IN CANCER PATIENTS
IMMUNOGEN, IC. ANNOUNCES THAT PHASE III TRIAL OF ONCOLYSIN B WILL BEGIN SOON
IMMUNOGEN BEGINS PHASE II TRIALS OF ONCOLYSIN S
IMMUNOGEN'S ONCOLYSIN B CONTINUES TO PREVENT RELAPSES IN LYMPHOMA PATIENTS
LIDAK PHARMACEUTICALS RECEIVES FDA CLEARANCE TO PROCEED WITH CANCER THERAPY CLINICAL TRIALS
ImmunoGen Drug Eradicates Large Human Colon Tumors in Mice Without Harmful Side Effects; Proceedings of the National Academy of Sciences Report
Immunogen Ends Development Of Oncolysin B

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters